Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
about
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryNelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotesIdentification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitorsIntracellular accumulation of human immunodeficiency virus protease inhibitorsIntact lipid rafts regulate HIV-1 Tat protein-induced activation of the Rho signaling and upregulation of P-glycoprotein in brain endothelial cellsSensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patientsIntracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.P glycoprotein in human immunodeficiency virus type 1 infection and therapy.Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing).The implications of P-glycoprotein in HIV: friend or foe?Transporter-mediated uptake into cellular compartments.Pharmacogenomics of CYP3A: considerations for HIV treatment.ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies.Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line.Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2).Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC.HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein.Effects of the membrane dipole potential on the interaction of saquinavir with phospholipid membranes and plasma membrane receptors of Caco-2 cells.The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition.Intracellular efavirenz levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected individualsAntiviral drugs with extra-cellular sites of action.Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.Gene expression modulation and the molecular mechanisms involved in Nelfinavir resistance in Leishmania donovani axenic amastigotes.High levels of P-glycoprotein activity in human lymphocytes in the first 6 months of life.The antiretroviral protease inhibitor ritonavir accelerates glutathione export from cultured primary astrocytes.Development of Therapeutic Agents: The Maternal-Fetal Perspective
P2860
Q28081272-F4633D35-DC1C-41B8-87AE-09709D986FBBQ28473470-B31B1E9A-9721-40AD-89ED-101AF9C9984DQ33807628-B62FE6FD-9E6D-402F-AC99-70DE57C75372Q33864976-89A674F5-773E-467B-ABFD-F3B37AF8D141Q34143531-97F9B348-227A-4FFD-91A9-E088EE83846AQ34170914-043362EF-25BB-48EC-9719-EB90AF26E0B3Q35006387-C403E2D0-7B59-413C-8202-1C3AB923AAE7Q35125760-14F8374B-71F0-4DD0-A998-1974589601B9Q35718765-B76DDB65-5F6B-4225-AD45-9B44E57CB32CQ36103626-1C39E98B-4472-4A48-9310-6A3EAA7BDEFBQ36135586-79AEA05D-164E-4F05-A0E1-CF435C6BB879Q36985076-05446268-CFD9-4005-92DA-52DFE0C7C318Q37419542-8FB60F32-E86B-4195-A4BA-23B1018A2C81Q37724178-B4567DF8-3259-45F1-AE59-9E0163208C99Q39356163-ED31B409-BA0A-4C03-AAED-9AF1920DD61AQ39657896-01A89AB8-5543-4649-BAF4-FCC924B1AD42Q39801648-FC80C51F-B695-4C6D-B45D-69C46988167AQ40162203-24B88167-B44F-4AA6-A023-97866D8DBC59Q40786787-16BCEFA4-2426-4A59-8252-E4F4969F77D3Q41811918-E51C1C5C-EF53-45FA-8AA7-AB24A257E7A9Q41829112-94124AE5-5548-4976-8F2C-402359100B70Q41915254-B8E09396-215F-4A92-8A5E-D0A5083578BEQ43759388-FA212972-00F4-4A24-87D1-75549B6208D7Q44261692-9922EFB6-9924-4CB7-9BE5-D3774C467913Q44606318-60FEC6F2-42AF-4A68-B372-624E509A04A3Q45302847-4383958C-98D4-490D-AE18-D3DC8947E4F9Q46226197-57782BAC-BDEA-4F72-8BAB-3C4424FABBF7Q48198876-36F4C060-AE2D-4E4C-81A2-0975E674AE79Q58862906-C273D6FB-8925-4517-883F-DFFD1AC5155E
P2860
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Differences in the intracellul ...... he effect of active transport.
@en
type
label
Differences in the intracellul ...... he effect of active transport.
@en
prefLabel
Differences in the intracellul ...... he effect of active transport.
@en
P2093
P1433
P1476
Differences in the intracellul ...... he effect of active transport.
@en
P2093
P304
P356
10.1097/00002030-200104130-00002
P407
P577
2001-04-01T00:00:00Z